Why there won't be relief from Zantac pain for GSK in the short term
The stock market is forward-looking and has already priced in a significant financial hit for GSK (GSK) from US litigation associated with claims its Zantac heartburn treatment might have links to cancer.The first court case, due...
18 August 2022